Baekeland Fonds Home Baekeland Fonds I Baekeland Fonds II English Nederlands
Trinean haalt 3,5 miljoen euro op PDF

Trinean NV, an innovative player in the sector of molecular instrumentation, today announced the closure of a 3,5 million € round of financing. The round was co-lead by new investor Vesalius Biocapital and existing investors Capital-E and Baekeland Fonds II.

Trinean is a spin-off of the University of Ghent (Intec) and IMEC. The company develops and markets the first nanoliter spectrophotometer with corresponding micro fluidic consumables allowing full spectrum UV/VIS spectroscopic measurements in droplets of liquids between 0,5 and 2,5 microliter. The initial target application is the determination of DNA/RNA concentrations in small sample volumes. This is of great importance to the biotech industry where today valuable DNA/RNA material has to be sacrificed in order to measure these concentrations, and where test procedures are time consuming. Next to DNA/RNA quantification, other applications will also be targeted such as ADME testing, protein concentration measurements, enzymology, nephelometry and clinical diagnostics.

The investment round will allow Trinean to start production, bring its products to the market and develop new applications.

The company is run by a senior management team consisting of Jan Boon (COO), (ex-Elscolab, Thermo Life Sciences, Flow Laboratories , Pharmacia Diagnostics….) and Prof. Marc Zabeau (CEO) (ex- Plant Genetic Systems, Helix, KeyeGene, Genscope, Methexis…).

For further information please contact: Jan Boon, COO Dulle Grietlaan, 17/3 B-9050 Gentbrugge. Tel.: 09 272 7535 -